Insulet Corp

NASDAQ:PODDUnited States

Insulet Corporation is primarily engaged in the development, manufacture and sale of its Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) that the user fills with insulin and wears directly on the body for up to three days at a time, which delivers personalized doses of insulin, and the Personal Diabetes Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with the user's personalized insulin-delivery instructions and wirelessly monitors the Pod's operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta.

Contact Information

Headquarters

100 Nagog ParkACTON, MA, United States 01720-3440

Phone

978-600-7000

Fax

978-600-0120

Executives

Independent Chairman of the Board

Timothy Scannell

President, Chief Executive Officer, Director

James Hollingshead

Chief Financial Officer, Executive Vice President, Treasurer

Wayde McMillan

Chief Human Resource Officer, Senior Vice President

Dan Manea

Executive Vice President - Innovation, Strategy and Digital Products

Eric Benjamin